Charlton S T, Davis S S, Illum L
School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK.
J Control Release. 2007 Apr 2;118(2):225-34. doi: 10.1016/j.jconrel.2006.12.014. Epub 2006 Dec 23.
There is an increasing need for nasal drug delivery systems that could improve the efficiency of the direct nose to brain pathway especially for drugs for treatment of central nervous system disorders. Novel approaches that are able to combine active targeting of a formulation to the olfactory region with controlled release bioadhesive characteristics, for maintaining the drug on the absorption site are suggested. If necessary an absorption enhancer could be incorporated. Low methylated pectins have been shown to gel and be retained in the nasal cavity after deposition. Chitosan is known to be bioadhesive and also to work as an absorption enhancer. Consequently, two types of pectins, LM-5 and LM-12, together with chitosan G210, were selected for characterisation in terms of molecular weight, gelling ability and viscosity. Furthermore, studies on the in vitro release of model drugs from candidate formulations and the transport of drugs across MDCK1 cell monolayers in the presence of pectin and chitosan were also performed. Bioadhesive formulations providing controlled release with increased or decreased epithelial transport were developed. Due to their promising characteristics 3% LM-5, 1% LM-12 pectin and 1% chitosan G210 formulations were selected for further biological evaluation in animal models.
对于能够提高直接鼻至脑途径效率的鼻腔给药系统的需求日益增加,特别是对于治疗中枢神经系统疾病的药物。有人提出了一些新方法,这些方法能够将制剂对嗅觉区域的主动靶向与控释生物粘附特性相结合,以将药物维持在吸收部位。如有必要,可加入吸收促进剂。低甲基化果胶已被证明在沉积后会在鼻腔内形成凝胶并保留。壳聚糖已知具有生物粘附性,并且还可作为吸收促进剂。因此,选择了两种类型的果胶,即LM-5和LM-12,以及壳聚糖G210,对其分子量、凝胶化能力和粘度进行表征。此外,还进行了关于候选制剂中模型药物的体外释放以及在果胶和壳聚糖存在下药物跨MDCK1细胞单层转运的研究。开发了具有控释功能且上皮转运增加或减少的生物粘附制剂。由于其具有良好的特性,选择了3% LM-5、1% LM-12果胶和1%壳聚糖G210制剂在动物模型中进行进一步的生物学评价。